7 results about "Lysophosphatidic acid" patented technology

The invention relates to the technical field of grease processing, and discloses a method for increasing the sn-2 DHA content in schizochytrium limacinum triglyceride. The method comprises the following steps: adding a metabolic regulator into a fermentation culture solution containing schizochytrium limacinum, carrying out fermentation culture until the total fermentation time is more than 120 hours, and collecting a grease product, the metabolic regulator is selected from at least one of choline chloride, inositol and lysophosphatidic acid. According to the method provided by the invention, the lipid metabolic flux of schizochytrium limacinum can be effectively regulated and controlled, and directional enrichment of DHA to the sn-2 site of triglyceride is remarkably promoted, so that the yield and content of sn-2 DHA are improved.

The application provides a mycoplasma hyopneumoniae culture medium capable of significantly improving the strain titer and an application thereof, and belongs to the field of veterinary biological products. The mycoplasma hyopneumoniae culture medium is obtained by adding L-asparagine, myo-inositol, arachidonic acid, urea, histamine, sodium pyruvate, valproic acid, glyceric acid, lysophosphatidic acid, L-citrulline, L-glutamine and L-leucine into a KM2 culture medium containing Bama pig serum. The culture medium can significantly improve the growth rate and viable bacterial titer of the mycoplasma hyopneumoniae under a low serum concentration, and reduces the production cost.

The invention relates to the technical field of microbial oil processing, and discloses a method for increasing the content of phospholipid DHA in schizochytrium limacinum oil. The method comprises the following steps: adding a metabolic regulator into a fermentation culture solution containing schizochytrium limacinum, carrying out fermentation culture until the total fermentation time is 90-120 hours, and collecting a grease product, the metabolic regulator is selected from at least one of choline chloride, ethanolamine, inositol and lysophosphatidic acid. According to the method provided by the invention, the lipid metabolic flux of schizochytrium limacinum can be effectively regulated and controlled, and directional enrichment of DHA to phospholipid components is remarkably promoted, so that the yield and content of phospholipid DHA are improved.

The present application belongs to the field of biosynthesis, and particularly relates to pyrophosphate lyddane diol ester synthase and yeast engineering bacteria for producing sclareol. In order to solve the problem of generally low yield of sclareol biosynthesis in the prior art, the pyrophosphate lyddane diol ester synthase is mutated and optimized in the present application, and a SsLPPs mutant containing at least one mutation of D730L, D374L, N674L or G379M is obtained, and the mutant is used for sclareol synthesis. Meanwhile, in order to solve the problem of genetic instability existing in the expression of free plasmid in part of saccharomyces cerevisiae strains, the present application constructs a sclareol synthesis pathway in the yeast genome, and at the same time, the acetyl coenzyme A synthesis pathway, the MVA pathway and the sclareol synthesis pathway are strengthened, and part of the transcriptional repressor is knocked out, so that the bottom bacteria for synthesizing sclareol are modified. The yield in a 5 L fermenter reaches 26.11 g / L, and the yield is greatly improved compared with the prior art.

The application discloses a wheat Tilletia indica-specific biomarker combination, a screening method and application thereof, and the biomarker combination comprises 20-hydroxyarachidonic acid, 1-octadecyl lysophosphatidic acid, linolenic acid, 13-hydroxydocosahexaenoic acid, 4-methoxy estrone, hypoxanthine, 3-hydroxymyristic acid, beta-ecdysterone, 17-phenyltrinorprostaglandin F2 alpha cyclopropylmethylamide, 11,12-dihydroxyeicosatrienoic acid and oxidized octadecadienoic acid. When the biomarker combination is used for identifying Tilletia indica, the time-consuming long and the accuracy easily interfered by the spore development stage limitations of traditional morphological identification are overcome; in view of the molecular level identification difficulty caused by the high genome homology of Tilletia indica and Tilletia controversa, the application digs the feature difference at the level of metabolomics, and constructs a specific chemical fingerprint, so that the technical bottleneck that the close relatives are difficult to accurately distinguish is effectively solved.

The invention provides a characteristic phospholipid molecular biomarker in plasma, a screening method thereof and application of the characteristic phospholipid molecular biomarker in preparation of a kit for diagnosing pneumoconiosis. The characteristic phospholipid molecules at least comprise the following nine phospholipid molecules: lysophosphatidylcholine (12: 0), phosphatidylcholine (16: 0 / 16: 0), phosphatidylcholine (18: 0 / 18: 1), phosphoinositide (16: 0 / 18: 1), lysophosphatidic acid (16: 0), phosphatidyl glycerol (16: 0 / 16: 0), phosphatidylserine (18: 1 / 18: 1), phosphatidylcholine (18: 0 / 20: 2) and lysophosphatidyl ethanolamine (18: 2). The TC value is calculated by calculating the quantitative values of the nine characteristic phospholipid molecules and a classification model constructed based on a support vector machine algorithm, the risk of pneumoconiosis is predicted according to the TC value, pneumoconiosis patients and non-pneumoconiosis patient groups can be accurately distinguished, and the method is used for pneumoconiosis diagnosis and early screening.

The present disclosure relates to compositions and methods for generating organoids having apical-out polarity or apical-in polarity. In particular, the disclosure provides methods for controlling the polarity (i.e. apical-out or apical-in) of organoids through culturing a population of cells (e.g., patient derived organoids) (e.g., undifferentiated organoid tissue) (e.g., pluripotent stem cell (PSC) derived organoids). To direct apical-out organoids, the disclosure provides methods where an organoid medium is used comprising one or both of lysophosphatidic acid (LPA) and sphingosine-1-phosphate (S1P). To direct apical-in organoids, the disclosure provides methods through culturing a population of cells (e.g., patient derived organoids) (e.g., undifferentiated organoid tissue) (e.g., PSC derived organoids) with an organoid medium lacking LPA and S1P.